Trade Names:Beconase AQ- Spray 42 mcg/actuation
Trade Names:QVAR- Aerosol 40 mcg/actuation- Aerosol 80 mcg/actuationApo-Beclomethasone (Canada)Gen-Beclo AQ (Canada)Propaderm (Canada)ratio-Beclomethasone AQ (Canada)Rivanase AQ (Canada)
Has potent anti-inflammatory effect on respiratory tract and in nasal passages.
Rapidly absorbed.Oral inhalation
Systemic bioavailability from lungs is about 20%.Nasal inhalation
Primarily deposited in the nasal passage; majority of the drug is eventually swallowed. Bioavailability following administration is 44%.
87% protein bound.
Metabolized to beclomethasone 17-monopropionate (active) and free beclomethasone (very weak activity).
Primarily excreted in feces. Less than 10% excreted in urine. The t ½ is 2.8 h for beclomethasone 17-monopropionate.
Within 24 h (oral inhalation). Within 3 days (nasal inhalation)
Maintenance prophylactic treatment of asthma in patients 5 yr of age and older; asthma patients requiring systemic corticosteroid administration in which adding an inhaled corticosteroid may reduce or eliminate need for systemic corticosteroids.Nasal inhalation
Relief of symptoms of seasonal or perennial allergic and nonallergic rhinitis; prevention of recurrence of nasal polyps following surgical removal.
Primary treatment of status asthmaticus or acute episodes of asthma; hypersensitivity to any of the ingredients.Nasal inhalation
PO Oral inhalation If previous therapy consisted of bronchodilators alone, start with 40 or 80 mcg twice daily (max dose, 320 mcg twice daily); if previous therapy consisted of inhaled corticosteroids, start with 40 to 160 mcg twice daily (max dose, 320 mcg twice daily).Children 5 to 11 yr of age
PO Oral inhalation If previous therapy consisted of bronchodilators alone or inhaled corticosteroids, start with 40 mcg twice daily (max dose, 80 mcg twice daily).Seasonal or Perennial Allergic and Nonallergic Rhinitis; Prevention of Recurrence of Nasal Polyps after Surgical RemovalAdults and Children 12 yr of age and older
Nasal inhalation 1 or 2 inhalations (42 to 84 mcg) in each nostril twice daily (168 to 336 mcg/day).Children 6 to 12 yr of age
Nasal inhalation 1 inhalation in each nostril twice daily (168 mcg/day). Patients not adequately responding or those with more severe symptoms may use 2 inhalations in each nostril twice daily (336 mcg/day). Once adequate control is achieved, decrease dose to 1 inhalation in each nostril twice daily (168 mcg/day). Max total daily dosage should not exceed 2 sprays in each nostril twice daily (336 mcg/day).
Oral inhalation: Store at 59° to 86°F on the concave end of the canister with the plastic actuator on top. For optimal results, canister should be at room temperature when used. Do not use actuator with any other inhalation drug product. Do not puncture canister or use near heat or open flame or discard into fire or incinerator. Nasal inhalation: Store between 59° and 86°F.
None well documented.
None well documented.
Headache (at least 3%).Nasal inhalation
Headache, light-headedness (less than 5%).
Pharyngitis, rhinitis, sinusitis (at least 3%).Nasal inhalation
Nasopharyngeal irritation (24%); sneezing attacks (4%); nasal stuffiness, nosebleeds, rhinorrhea, tearing eyes (less than 3%); dryness, irritation of the nose and throat, unpleasant taste and smell.
Nausea (at least 3%).Nasal inhalation
Nausea (less than 5%).
Dysmenorrhea (1% to 3%).
Suppression of hypothalamic-pituitary-adrenal (HPA) function.
Increased asthma symptoms, upper respiratory tract infections (at least 3%); coughing (1% to 3%).
Growth velocity reduction in children; rare cases of immediate and delayed hypersensitivity reaction with angioedema, bronchospasm, rash, and urticaria; weight gain.Oral inhalation
Back pain, dysphonia, oral symptoms, pain (at least 3%).
If change is made from systemic (oral) corticosteroids to inhaled or intranasal corticosteroids, observe patient carefully for signs of adrenal insufficiency (eg, depression, dizziness, fatigue, hypotension, nausea, or abdominal, joint, or muscle pain). Deaths caused by adrenal insufficiency have occurred during and after conversion to aerosol corticosteroids. If nasal spray is used for several months or longer, periodically examine for changes in the nasal mucosa.
Category C .
Undetermined. Because other corticosteroids are excreted in human milk, use caution.
Safety and efficacy in children younger than 5 yr of age not established (oral inhalation). Safety and efficacy in children younger than 6 yr of age not established (nasal inhalation). Corticosteroids may suppress growth in children and adolescents, particularly with higher doses over extended periods.
Immediate and delayed hypersensitivity reactions have occurred.
Not indicated for relief of bronchospasm.
Antifungal treatment or discontinuance of corticosteroid therapy may be necessary.
Patients receiving immunosuppressant agents are more susceptible to infections than healthy adults. If a patient is exposed to measles or chickenpox, appropriate prophylaxis and treatment may be indicated.
Use cautiously in patients taking daily or alternate-day prednisone; may increase likelihood of HPA function suppression. Exceeding recommended dose may cause systemic effects.
Use extreme caution when transferring patient from systemic corticosteroid to less systemically available inhaled corticosteroid because death caused by adrenal insufficiency has occurred in asthmatic patients.
Patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use a nasal corticosteroid until healing has occurred.
Copyright © 2009 Wolters Kluwer Health.